Artax Biopharma
Total Raised
$44.18MInvestors Count
7Deal Terms
2Artax Biopharma Funding, Artax Biopharma Valuation & Artax Biopharma Revenue
7 Fundings
Artax Biopharma's latest funding round was a Series C for $26M on January 3, 2022.
Artax Biopharma's valuation in September 2015 was $13.33M.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
1/3/2022 | Series C | $26M | Advent Life Sciences, Belinda Termeer, Columbus Venture Partners, Eli Lilly and Company, Sound Bioventures, and Undisclosed Investors | 3 | ||
2/26/2021 | Debt - II | |||||
4/29/2020 | Series B - III | |||||
8/12/2019 | Series B - II | |||||
9/22/2015 | Series B | ▲$13.33M |
Date | 1/3/2022 | 2/26/2021 | 4/29/2020 | 8/12/2019 | 9/22/2015 |
|---|---|---|---|---|---|
Round | Series C | Debt - II | Series B - III | Series B - II | Series B |
Amount | $26M | ||||
Investors | Advent Life Sciences, Belinda Termeer, Columbus Venture Partners, Eli Lilly and Company, Sound Bioventures, and Undisclosed Investors | ||||
Valuation | ▲$13.33M | ||||
Revenue | |||||
Sources | 3 |
Artax Biopharma Deal Terms
2 Deal Terms
Artax Biopharma's deal structure is available for 2 funding rounds, including their Series B from September 22, 2015.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Artax Biopharma Investors
7 Investors
Artax Biopharma has 7 investors. Advent Life Sciences invested in Artax Biopharma's Series C funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
9/22/2015 | 1/3/2022 | 4 Series B, Series B - II (2019), Series B - III (2020), Series C (2022) | Venture Capital | United Kingdom | ||
Venture Capital | Spain | |||||
Corporation | Indiana | |||||
Angel Investor (Individual) | Massachusetts | |||||
Venture Capital | Sweden |
First funding | 9/22/2015 | ||||
|---|---|---|---|---|---|
Last Funding | 1/3/2022 | ||||
Investor | |||||
Rounds | 4 Series B, Series B - II (2019), Series B - III (2020), Series C (2022) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Corporation | Angel Investor (Individual) | Venture Capital |
Location | United Kingdom | Spain | Indiana | Massachusetts | Sweden |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.